DUBLIN--(BUSINESS WIRE)--The "Central Nervous System - Disease & Epidemiology Overview" report from Decision Resources Group has been added to ResearchAndMarkets.com's offering.
This report provides a disease market overview for each indication and global epidemiology overviews for each indication.
The Central Nervous System Disease & Epidemiology Overview report provides disease market overviews and global epidemiology overviews for 28 indications in the Central Nervous System therapy area:
Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Autism, Epilepsy, Friedreich's Ataxia, Huntington's Disease, Ischemic Stroke, Multiple Sclerosis, Muscular Dystrophy, Parkinson's Disease, Spinal Muscular Atrophy, Traumatic Brain Injury, Cancer Pain, Chronic Low Back Pain, Chronic Pain, Migraine, Neuropathic Pain, Osteoarthritic Pain, Postoperative Pain, Attention-Deficit-Hyperactivity Disorder, Bipolar Disorder, Borderline Personality Disorder, Narcolepsy, Obsessive-Compulsive Disorder, Opioid Addiction, Post Traumatic Stress Disorder, Schizophrenia and Unipolar Depression Disease.
The disease market overviews include information such as market size forecasts, prevailing treatment trend analysis and predictions, key areas of unmet need, current and emerging therapies, physician (KOL) insights, clinical pipeline analysis, and more, for each indication.
The global epidemiology overviews provide insights including global diagnosed prevalence, diagnosed prevalence by region, 10-year diagnosed prevalence growth forecast, relative sizes of the factors contributing to the trend in prevalent cases, and more, for each indication.
Key Topics Covered:
- About the Analyst
- About the analyst's Epidemiology
- Disease Landscape and Insight Overview
- Epidemiology Overview
Companies Mentioned
- Pfizer
- Eli Lilly
- Regeneron
- Teva
- Mitsubishi
- Tanabe
For more information about this report visit https://www.researchandmarkets.com/research/knvckb/central_nervous?w=4
